The CAR-T company cancels its Nasdaq IPO after securing more in a Novartis-led private financing.
Perhaps sensing trouble ahead Kiadis diversifies beyond ATIR101 by buying Cytosen, but it is a scientific appointment that will cause real excitement.
A Baylor College study suggests to investors what Bellicum’s upcoming first-in-human trial of BPX-603 will have to match.
The UK ortho and woundcare group might yet pounce on Nuvasive.
Five months after Allogene’s flotation there are few signs of waning interest in new issues of cell therapy companies, and they all have one thing in common.
After a trial failure last week, Caladrius Biosciences has not abandoned hope for its T regulatory cell therapy in type 1 diabetes, but funding might become a problem.
Promising retinitis pigmentosa results have given Reneuron a boost, but the company still faces a pivotal trial.
As Gilead bows out of BCMA, Novartis pins its hopes on a BCMA/CD19 combo.
The company’s nascent CAR-T portfolio includes technology licensed from one of the field’s most prominent pioneers.